• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Optimal two-stage design for a series of pilot trials of new agents.

作者信息

Yao T J, Venkatraman E S

机构信息

Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

出版信息

Biometrics. 1998 Sep;54(3):1183-9.

PMID:9750258
Abstract

An approach to determine the appropriate sample sizes for a series of screening trials to identify promising new therapeutic agents was presented by Yao, Begg, and Livingston (1996, Biometrics 52, 992-1001). This approach is now improved to a two-stage design that further minimizes the time to identify a promising agent under fixed error rates. When applied to data from the historical experience of exploratory vaccination trials at Memorial Sloan-Kettering Cancer Center, the method demonstrates that relatively small individual screening trials are optimal. The reliability of the results is evaluated using the bootstrap.

摘要

相似文献

1
Optimal two-stage design for a series of pilot trials of new agents.
Biometrics. 1998 Sep;54(3):1183-9.
2
Optimal sample size for a series of pilot trials of new agents.一系列新型药物先导试验的最佳样本量
Biometrics. 1996 Sep;52(3):992-1001.
3
An optimal design for screening trials.
Biometrics. 1998 Mar;54(1):243-50.
4
Dendritic cell vaccines in melanoma: from promise to proof?黑色素瘤中的树突状细胞疫苗:从希望到验证?
Crit Rev Oncol Hematol. 2008 May;66(2):118-34. doi: 10.1016/j.critrevonc.2007.12.007. Epub 2008 Feb 8.
5
Optimal and minimax three-stage designs for phase II oncology clinical trials.肿瘤学II期临床试验的最优和极小极大三阶段设计。
Contemp Clin Trials. 2008 Jan;29(1):32-41. doi: 10.1016/j.cct.2007.04.008. Epub 2007 May 6.
6
[General principles and first clinical trials of therapeutic vaccines against cancer].[癌症治疗性疫苗的一般原则及首次临床试验]
Bull Cancer. 2008 Mar;95(3):327-35. doi: 10.1684/bdc.2008.0588.
7
Melanoma vaccines: achievements and perspectives.黑色素瘤疫苗:成就与展望。
Forum (Genova). 2003;13(2):144-54; quiz 189.
8
Sample size re-estimation in group-sequential response-adaptive clinical trials.成组序贯反应自适应临床试验中的样本量重新估计
Stat Med. 2003 Dec 30;22(24):3843-57. doi: 10.1002/sim.1677.
9
A SAS macro for sample size adjustment and randomization test for internal pilot study.用于内部预试验样本量调整和随机化检验的SAS宏程序。
Comput Methods Programs Biomed. 2008 Apr;90(1):66-88. doi: 10.1016/j.cmpb.2007.11.016. Epub 2008 Jan 14.
10
Therapeutic cancer vaccines: using unique antigens.治疗性癌症疫苗:使用独特抗原。
Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14653-6. doi: 10.1073/pnas.0404839101. Epub 2004 Aug 5.

引用本文的文献

1
A Bayesian pick-the-winner design in a randomized phase II clinical trial.随机II期临床试验中的贝叶斯选优设计。
Oncotarget. 2017 Jul 7;8(51):88376-88385. doi: 10.18632/oncotarget.19088. eCollection 2017 Oct 24.
2
Bayesian adaptive phase II screening design for combination trials.贝叶斯自适应Ⅱ期联合试验筛选设计。
Clin Trials. 2013;10(3):353-62. doi: 10.1177/1740774512470316. Epub 2013 Jan 28.
3
Bayesian optimal design for phase II screening trials.用于II期筛选试验的贝叶斯最优设计。
Biometrics. 2008 Sep;64(3):886-894. doi: 10.1111/j.1541-0420.2007.00951.x. Epub 2007 Dec 20.
4
Proper inference from Simon's two-stage designs.从西蒙两阶段设计中进行正确推断。
Stat Med. 2008 Jul 20;27(16):3145-54. doi: 10.1002/sim.3123.